NICE rejection for CSL Behring gene therapy
Therapy is a treatment option for adults with severe and moderately severe haemophilia B
Read More
Tag: CSL Behring
Firms form alliance to work on COVID-19 therapy
The alliance will immediately start work on the development of an unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine
Read More
Draft NICE decision rejects Respreeza for incurable, genetic disorder
NICE has published draft guidelines rejecting NHS use of CSL Behring’s Respreeza for treating emphysema in adults with severe alpha-1-proteinase inhibitor deficiency.
Read More
US nod for CSL Behring’s Hizentra
US regulators have cleared CSL Behring’s Hizentra for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder affecting the peripheral nerves that can cause permanent nerve damage.
Read More
US nod for CSL Behring’s HAE prevention therapy
US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adults
Read More
FDA nod for CSL’s long-acting haemophilia drug
CSL Behring’s Afstyla has been approved in the US as a long-lasting treatment option for patients with the bleeding disorder haemophilia A.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
